Appendix 1: Study form

Date of the procedure: __ - __ - 20__ Patient Initials: _ _ _ ID:______________
Center:___
Date of birth:__/__/_____ Gender: ○M / F○ Contact data:
Supervising Endoscopist &ID: ___________   Trainee &ID:_______

Procedu rtype: ○ first attempt ○ second attempt (previous failure)

1. Indication of the procedure:
   ○ CBD stones (1) Bile leak/ trauma (5)
   ○ Benign stricture (2) Stent exchange (6)
   ○ Malignant stricture (3) Chronic pancreatitis (7)
   ○ Sclerosing cholangitis (4) Other (8)

Final Diagnosis: ____________________________ Difficulty level: ○1 ○2 ○3

Papilla anatomy:
   ○ Native papilla (1) ○ Preexisting sphincterotomy (2)
   ○ Associated diverticulum (4) ○ Modified anatomy (3)

Cannulation method (check ONE): Time to cannulation:
   ○ Sphincterotome + guidewire <5minutes ○
   ○ Contrast guided 5-10 minutes ○
   ○ Precut >10 minutes ○
   ○ Double guide-wire (pancreas + biliary) failed ○
   ○ Other _____________________________

Difficult cannulation? ○ YES / NO ○ PD accessed? ○ YES / NO ○ PD stent? ○ YES / NO ○

Precut type (if applicable): NK papillotomy (1) NK fistulotomy (2) Septotomy (3)

Procedure:
   ○ successful stone extraction (1) ○ partial success, reintervention planned (4)
   ○ successful stenting of stricture (2) ○ failed procedure, reintervention planned (5)
   ○ successful sphincterotomy (3) ○ failed procedure, different treatment required (6)

Trainee involved: ○ YES ○ NO => If YES, please describe:
   ○ failed cannulation attempts (1)
   ○ selective cannulation of the desired duct (2)
   ○ partially completed the procedure, required the intervention of an expert supervisor (3)
   ○ completed the procedure (4)
**Sedation:**
- none
- superficial sedation (midazolam)
- deep sedation/general anesthesia

2. **Procedure-related adverse events**

- No adverse events (1)
- Reintervention required (< 7 days) (2)
- Failure of the initial procedure (3)
- Cholangitis (4)
- Postsphincterotomy bleeding (5)
- Acute pancreatitis (6)
- Perforation (7)
- Death (up to 30 days after ERCP) (8)
- Other (………………………………) (9)

3. **Severity of the adverse event (when applicable):**

- Mild (increased the hospital stay 1-3 days)
- Moderate (increased the hospital stay 4-9 days)
- Severe (required surgery/admission in the ICU/increased hospital stay > 10 days)
- Death (resulting as a direct complication of the procedure)

4. **Total bilirubin levels (max. 24 hours prior to the procedure):** …… mg/dL

5. **Lipase / Amylase levels at 6hrs postERCP (please specify):** …… IU/mL